Table 2.

Characteristics of included studies

Sl no.	Author/year	Study design	Level of evidence	Treatment Groups	Number of patients	Male/female	Mean age (year) with SD	BMI	KL Stage/Ahlback grade	Follow up in months
1	Crowley et al. 2009 [11]	RCT	I	UC-II	26	13/13	58.9±9.79	NR	NR	3
				G+C	26	17/9	58.7±10.3	NR	NR	3
2	Lugo et al. 2015 [13]	RCT	I	UC-II	63	33/30	53.5±0.99	25.2±0.37	II-42, III-21	6
				GC	65	28/37	52.6±1.02	25.5±0.40	II-45, III-20	6
				Placebo control	58	28/30	53.1±1.02	24.7±0.40	II-39, III-19	6
3	Bakilan et al. 2016 [14]	RCT	I	AC+CII	20	1/19	57.65±8.73	30.20±5.27	II-16, III-4	3
				AC	19	2/17	58.84±6.55	27.9±4.16	II-18, III-1	3
4	Costa et al. 2020 [15]#	RCT	I	CPG	20	6/14	55.45±8.78	30.15±4.85	I-1, II-12, III-7	6
				PCPG	20	4/16	57.35±11.44	30.34±5.66	I-2, II-10, III-8	6
5	Costa et al. 2021 [16]*	RCT	I	UC-II (CG-group)	20	7/13	60.25±7.45	26.95±3.84	I-2, II-11, III-7	6
				Placebo	20	6/14	57.60±6.96	30.01±4.47	I-4, II-7, III-9	6
6	Rui et al. 2021 [9]	RCT	I	UC-II	28	13/15	59.40 (4.9)	22.60 (1.8)	I-17, II-11	3
				PC	27	11/16	61.61 (1.3)	23.80 (2.2)	I-16, II-11	3
7	Sadigursky et al. 2022 [17]	RCT	II	UC-II	53	18/35	68.7±5.3	27.9±2.4	II-22, II-31	3
				Control	52	18/34	68.6±6.0	27.9±1.5	II-20, II-32	3
8	Santana et al. 2022 [18]	RCT	I	UC-II	13	0/13	54.1±7.9	29.6±5.2	Ahlback 2-4	3
				Control	13	0/13	61±6.6	33.1±7.3	Ahlback 2-4	3
				EG	13	0/13	60±10.8	35.3±6.6	Ahlback 2-4	3

RCT-Randomized control trial, UC-Undenatured Collagen, GC-Glucosamine HCl+Chondroitin Sulfate, AC+CII-Acetaminophen + Native Type II Collagen, AC-Acetaminophen, CPG-collagen + physiotherapy group, PCPG-placebo collagen + physiotherapy group, PC-positive control group, EG-exercise group.

^#out of 3 groups only two groups shown here relevant tour review.

^*out of 5 groups in the study we have included only two groups relevant to our review.

BMI-Body mass index.